Company Summary:

FL87, Inc. is a privately held, early-stage biotechnology company developing a novel approach to gene therapy that can address currently untreatable diseases.

FL87 was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Moderna (MRNA), Syros Pharmaceuticals (SYRS), Seres Therapeutics (NASDAQ:MCRB), Generate Biomedicines, Tessera Tx, Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary:

We are searching for an experienced and enthusiastic Associate Scientist/Scientist I to lead the development of novel methods to manufacturing of novel nucleic acid therapeutics. We are looking for an individual who enjoys hands-on laboratory benchwork and brings scientific rigor and intellectual curiosity to their role. This individual will have the opportunity to work in a dynamic and fast-paced entrepreneurial environment as part of a highly collaborative and rapidly growing team.

Key Responsibilities:

Work with the team to drive advancement of platform development developing methods for scalable, rigorous, and cost-effective manufacturing and quality control. Step into benchwork to execute platform goals with tenacity, agility, and timeliness. 

• The successful candidate will work as part of the team responsible for the development, characterization, and production of nucleic acid therapeutics
• Synthesize and purify routine nucleic acid products for preclinical studies
• Help establish and optimize nucleic acid manufacturing scale-up capability
• Help develop scalable strategies for upstream and downstream nucleic acid production
• Carry out process development studies using the design-of-experiments approach
• Analyze, summarize, and present experimental results to team members and management
• Explore new technologies and methods to optimize current processes in fast-paced research environment
• Maintain up-to-date records and communicate results to team members in written technical reports and oral presentations
• Participate in experimental design and troubleshooting efforts
• Interpret, summarize experimental data and maintain excellent laboratory notebooks

Qualifications:

• PhD (0-1 years) or M.S. (5+ years) in Biochemistry, Chemical Engineering, Chemistry, or related field
• Proven track record of scaling up upstream production and purification of nucleic acid therapeutics
• Molecular biology experience with experience in enzyme processes and optimization, IVT and/or other isothermal amplification, and PCR
• Hands-on skills on AKTA with UNICORN control software and filtration technologies such as Repligen TFF system

• • Attention to detail, ability to multi-task, and trouble-shoot
  • Strong written and verbal communication skills
  • Excellent record keeping and data management skills
  • The ideal candidate is adaptable, enthusiastic about new challenges, has an innate curiosity, and a passion for learning
  • Experience working in fast-paced startup environments
  • Excellent organization skills, approaching tasks with efficiency
  • Ability to analyze, summarize, and communicate scientific data
  • Ability to work independently while effectively interacting and collaborating in a team environment

More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.

We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.  Learn more about our Company Creation Model. Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO.

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.

#LI-SO1